CPZEN-45 Antibacterial Compound for Resistant Tuberculosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective pharmaceutical efficacy against extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB) bacteria, which are resistant to multiple antibiotics, posing a significant challenge in tuberculosis management.
Innovation Solution
The development of a compound, CPZEN-45, with a specific structural formula, is used as an anti-XDR-TB drug, anti-MDR-TB drug, and in combination with rifampicin and isonicotinic acid hydrazide, to treat tuberculosis bacteria, demonstrating excellent antibacterial activity against resistant strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-tuberculosis drugs are used, then treatment is effective against drug-sensitive tuberculosis, but it becomes ineffective against extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB)
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of caprazamycin to create compound (1) with specific structural features (including a fluorine atom at position 6 and specific stereochemistry) that enable it to overcome bacterial resistance mechanisms. This structural parameter change allows the compound to maintain effectiveness against XDR-TB and MDR-TB strains that have developed resistance to conventional anti-tuberculosis drugs.
Solution Approach 2:
The patent employs composite materials by creating a hybrid molecule that combines caprazamycin core structure with specific substituents (fluorine atom, hydroxymethyl group, and other functional groups). This composite molecular structure integrates the advantages of different chemical features to achieve broad-spectrum activity against both drug-sensitive and drug-resistant tuberculosis strains.
2Adaptability or versatility
If new anti-XDR-TB drugs are developed, then effectiveness against resistant strains improves, but pharmaceutical efficacy and safety need to be ensured
Solution Approach 1:
The patent applies feedback by conducting comprehensive in vitro and in vivo evaluations to assess the compound's antibacterial activity, pharmacokinetic properties, and safety profile. The feedback from these studies confirms that compound (1) exhibits potent activity against XDR-TB and MDR-TB strains with favorable pharmacological characteristics, ensuring its reliability as a therapeutic agent.
Solution Approach 2:
The patent optimizes pharmaceutical parameters by adjusting the dosage regimen, administration route, and formulation of compound (1) to achieve maximum therapeutic efficacy while minimizing side effects. The compound demonstrates appropriate pharmacokinetic parameters including absorption, distribution, metabolism, and excretion characteristics that support its use as a safe and effective anti-tuberculosis medication.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
An anti-XDR-TB drug including a compound having a structure expressed by Structural Formula (1) below; an anti-MDR-TB drug including a compound having a structure expressed by Structural Formula (1) below; and a combination anti-tuberculosis drug including a drug containing a compound having a structure expressed by Structural Formula (1) below, and at least one anti-tuberculosis drug selected from an anti-tuberculosis drug containing rifampicin (RFP) and an anti-tuberculosis drug containing isonicotinic acid hydrazide (INH).